Most affected individuals are clinically normal at birth. Since alpha-mannosidosis can be treated with BMT, and possibly also by ERT in the future, there is a pressing need for newborn screening to identify affected individuals early, before the onset of severe, irreversible, pathology [Meikle et al 2006].
